Lung cancer: Resolving resistance to ALK-targeted therapy
- PMID: 26806320
- DOI: 10.1038/nrclinonc.2016.8
Lung cancer: Resolving resistance to ALK-targeted therapy
Comment on
-
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23. N Engl J Med. 2016. PMID: 26698910 Free PMC article. Clinical Trial.
References
-
- N Engl J Med. 2016 Jan 7;374(1):54-61 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
